A Study of AZD8233 in Participants With Dyslipidemia

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

July 20, 2021

Study Completion Date

July 20, 2021

Conditions
Dyslipidaemia
Interventions
DRUG

AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

DRUG

Placebo

Placebo solution

Trial Locations (19)

2000

Research Site, Frederiksberg

2730

Research Site, Herlev

4000

Research Site, Roskilde

7501

Research Site, Trebišov

8200

Research Site, Aarhus N

8800

Research Site, Viborg

12553

Research Site, New Windsor

27408

Research Site, Greensboro

32216

Research Site, Jacksonville

33024

Research Site, Pembroke Pines

34452

Research Site, Inverness

45219

Research Site, Cincinnati

46260

Research Site, Indianapolis

58104

Research Site, Fargo

83646

Research Site, Meridian

85101

Research Site, Bratislava

95661

Research Site, Roseville

831 03

Research Site, Bratislava

048 01

Research Site, Rožňava

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY